Infliximab biosimilar - Pfizer

Drug Profile

Infliximab biosimilar - Pfizer

Alternative Names: Infliximab-Pfizer; PF-06438179; PF-6438179

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2014 Pfizer completes a phase I pharmacokinetics trial in Healthy volunteers in the USA (NCT01844804)
  • 01 May 2013 Phase-I clinical trials in Rheumatoid arthritis (in volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top